Cargando…

Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer

BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zheng-Yan, Wang, Xiao-Dong, Li, Mou, Liu, Xi-Jiao, Ye, Zheng, Song, Bin, Yuan, Fang, Yuan, Yuan, Xia, Chun-Chao, Zhang, Xin, Li, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243642/
https://www.ncbi.nlm.nih.gov/pubmed/32476800
http://dx.doi.org/10.3748/wjg.v26.i19.2388
_version_ 1783537443672162304
author Li, Zheng-Yan
Wang, Xiao-Dong
Li, Mou
Liu, Xi-Jiao
Ye, Zheng
Song, Bin
Yuan, Fang
Yuan, Yuan
Xia, Chun-Chao
Zhang, Xin
Li, Qian
author_facet Li, Zheng-Yan
Wang, Xiao-Dong
Li, Mou
Liu, Xi-Jiao
Ye, Zheng
Song, Bin
Yuan, Fang
Yuan, Yuan
Xia, Chun-Chao
Zhang, Xin
Li, Qian
author_sort Li, Zheng-Yan
collection PubMed
description BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC. METHODS: This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (n = 70) and a validation set (n = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram. RESULTS: Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation. CONCLUSION: A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC.
format Online
Article
Text
id pubmed-7243642
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-72436422020-05-30 Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer Li, Zheng-Yan Wang, Xiao-Dong Li, Mou Liu, Xi-Jiao Ye, Zheng Song, Bin Yuan, Fang Yuan, Yuan Xia, Chun-Chao Zhang, Xin Li, Qian World J Gastroenterol Retrospective Study BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC. METHODS: This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (n = 70) and a validation set (n = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram. RESULTS: Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation. CONCLUSION: A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC. Baishideng Publishing Group Inc 2020-05-21 2020-05-21 /pmc/articles/PMC7243642/ /pubmed/32476800 http://dx.doi.org/10.3748/wjg.v26.i19.2388 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Li, Zheng-Yan
Wang, Xiao-Dong
Li, Mou
Liu, Xi-Jiao
Ye, Zheng
Song, Bin
Yuan, Fang
Yuan, Yuan
Xia, Chun-Chao
Zhang, Xin
Li, Qian
Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title_full Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title_fullStr Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title_full_unstemmed Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title_short Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
title_sort multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243642/
https://www.ncbi.nlm.nih.gov/pubmed/32476800
http://dx.doi.org/10.3748/wjg.v26.i19.2388
work_keys_str_mv AT lizhengyan multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT wangxiaodong multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT limou multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT liuxijiao multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT yezheng multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT songbin multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT yuanfang multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT yuanyuan multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT xiachunchao multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT zhangxin multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer
AT liqian multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer